Slide 1: Business Finance Pipeline
Business Finance Pipeline Appendices
Slide 2: Results Q2 2024
Business Finance Pipeline Appendices Results Q2 2024 July 25, 2024
Slide 3: Forward-looking statements
Business Finance Pipeline Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projecti
Slide 4: Agenda
Business Finance Pipeline Appendices Agenda 01 Business Paul Hudson 02 Finance François Roger 03 Pipeline Houman Ashrafian 04 Q&A Presenters and Brian Foard, Thomas Triomphe, Olivier Charmeil, Julie Van Ongevalle, and Roy Papatheodorou 4 Investor Relations
Slide 5: Q2: strong performance with 10% sales growth; 2024 EPS guidance upgraded
Business Finance Pipeline Appendices Q2: strong performance with 10% sales growth; 2024 EPS guidance upgraded Dupixent Pharma launches1 • Dupixent: continued strong growth €3.3bn in all indications across geographies €0.7bn +29% • Pharma launches: broad-based, +80% strong performance Vaccines • Vacc
Slide 6: Dupixent: sales above €3bn in Q2; on track for ~€13bn in 2024
Business Finance Pipeline Appendices Dupixent: sales above €3bn in Q2; on track for ~€13bn in 2024 Sales (€m) Q2 performance Worldwide growth 29% #1 NBRx market driven by strong demand share across ALL 6,138 across US and other key approved indications1 markets (DE, JP, CN) 4,877 H2 2024 milestones
Slide 7: New launches: 7% of total Biopharma sales
Business Finance Pipeline Appendices New launches: 7% of total Biopharma sales 1 (€m) Q2 sales 168 158 121 114 54 37 26 182 11 €707m, +85% All changes at CER and for Q2 2024 unless stated otherwise. 1. Sanofi sales excluding Opella. 2. Limited sales due to global vaccine seasonality towards the seco
Slide 8: Flu: strengthening leadership
Business Finance Pipeline Appendices Flu: strengthening leadership Novavax partnership: Advancing H5 pandemic flu vaccine potential for a truly differentiated flu+COVID-19 combo vaccine preparedness with phase 1/2 studies • BARDA-sponsored egg-based protein Optimal Combining the proven efficacy of S
Slide 9: A comprehensive carbon transition plan; on track for 2030
Business Finance Pipeline Appendices A comprehensive carbon transition plan; on track for 2030 Current performance and estimated contribution of key reduction levers 1. Absolute scope 3 GHG from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation
Slide 10: Finance
Business Finance Pipeline Appendices Finance Q2 2024
Slide 11: Accelerating sales momentum from portfolio transformation
Business Finance Pipeline Appendices Accelerating sales momentum from portfolio transformation Sales (€m) FY 2023 vs. 2022 Q2 2024 vs. 2023 +8% reported Total +5% +10% growth +10% 10,983 Rest of -238 10,745 business 9% 1,018 Launches 4% Impact of 9,965 Aubagio, 3% 3% COVID-19 -2% -2% Q2 2023 Growth
Slide 12: Group P&L
Business Finance Pipeline Appendices Group P&L (€m) Q2 2023 Q2 2024 % change Sales Net sales 9,965 10,745 +10.2% +10.2%; broad-based across portfolio Other revenues 717 635 -10.3% Gross margin Gross profit 7,419 7,974 +10.4% -0.3pp, driven by currency, Aubagio and Gross margin % 74.5% 1 74.2% 1 -0.3
Slide 13: 2024 business dynamics improving; guidance upgraded
Business Finance Pipeline Appendices 2024 business dynamics improving; guidance upgraded Q3 2024 FY 2024 Sales • Dupixent, pharma launches: continued growth • Dupixent: target of ~€13bn • Aubagio: decreasing impact of EU loss of exclusivity (LoE) • Vaccines: expected to grow mid single-digit • Beyfo
Slide 14: Pipeline
Business Finance Pipeline Appendices Pipeline
Slide 15: Pipeline: Q2 major milestones
Business Finance Pipeline Appendices Pipeline: Q2 major milestones Regulatory New scientific collaborations Approvals • Formation Bio and OpenAI to accelerate drug development Dupixent COPD (EU) • Belharra strategic collaboration to advance the discovery of novel small-molecule therapeutics in immun
Slide 16: ATS: rilzabrutinib potentially the first advanced oral treatment for uncontrolled asthma
Business Finance Pipeline Appendices ATS: rilzabrutinib potentially the first advanced oral treatment for uncontrolled asthma Primary endpoint: Secondary endpoint: reduction in loss of asthma control improvement in asthma symptoms • Oral medicine targeting both Type 2 and non-Type 2 pathways (LOAC)
Slide 17: ASCO: Sarclisa the only anti-CD38 with phase 3 data in combo with VRd
Business Finance Pipeline Appendices ASCO: Sarclisa the only anti-CD38 with phase 3 data in combo with VRd for newly diagnosed transplant-ineligible MM patients Source: abstract 7500, 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (clinical trials identifier: NCT03319667). VRd: bor
Slide 18: Pipeline: increasing news flow
Business Finance Pipeline Appendices Pipeline: increasing news flow Dupixent – CSU (study C) lunsekimig – asthma rilzabrutinib – IgG4-related Dupixent – BP disease Oral TNFR1si – psoriasis itepekimab – COPD rilzabrutinib – wAiHA tolebrutinib – RMS Oral TNFR1si – RA venglustat – Fabry disease amlitel
Slide 19: Q&A session
Business Finance Pipeline Appendices Q&A session To ask a question By zoom By phone Any problems? Click on the Raise and lower your Email us: Raise hand icon hand: dial *9 investor.relations@sanofi.com Check your audio device Unmute and mute is well connected your microphone: dial *6
Slide 20: Finance appendices
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Finance appendices
Slide 21: Sales biopharma
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Sales biopharma Q2 2024 sales (€m) Change Dupixent 3,303 29.2% Polio/Pertussis/Hib vaccines including Boosters 712 -5.1% Lantus 398 21.0% Toujeo 313 11.0% Meningitis, Travel and En
Slide 22: Currency impact
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Currency impact Sales (€m) Business EPS (€) 16 -0.01 -238 -0.08 -484 -444 -0.13 -0.19 -0.22 -799 -922 -0.27 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 2023 2024 2023 2024 22 Investor Rela
Slide 23: Currency sensitivity and exposure
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Currency sensitivity and exposure 2024 Business EPS currency sensitivity Currency exposure on Q2 2024 sales Currency Change Business EPS sensitivity Others 15.7% US Dollar + 0.05 U
Slide 24: Net debt
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Net debt1 (€m) 667 15,112 2,493 4,704 7,793 858 545 -1,380 -568 Net debt FCF before Proceeds Asset Restructuring Dividends paid Acquisitions4 Other5 Net debt December 31, restructu
Slide 25: Sanofi accounting of collaboration with Novavax
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Sanofi accounting of collaboration with Novavax Co-exclusive license to co-commercialize COVID-19 vaccine and develop flu-COVID-19 combination vaccines COVID-19 vaccine1 Combinatio
Slide 26: Pipeline appendices
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Pipeline appendices
Slide 27: Pipeline: Q2 changes
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Pipeline: Q2 changes Regulatory KevzaraA IL6R mAb Polyarticular juvenile idiopathic arthritis Approved (US) Chronic obstructive pulmonary disease Approved (EU) Chronic spontaneous
Slide 28: Pipeline: registration and phase 3
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Pipeline: registration and phase 3 Registration Chronic obstructive pulmonary disease (US, JP, CN) DupixentA IL4/IL13 mAb Chronic spontaneous urticaria (EU) fitusiran1 RNAi targeti
Slide 29: Pipeline: phase 2
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Pipeline: phase 2 Immunology Rare diseases DupixentA IL4/IL13 mAb Ulcerative colitis rilzabrutinib BTK inhibitor Warm autoimmune hemolytic anemia itepekimabA IL33 mAb Bronchiectasi
Slide 30: Pipeline: phase 1
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Pipeline: phase 1 Immunology Oncology SAR444336 Non-beta IL2 SynthorinTM Inflammatory indication SAR444881J ILT2 mAb Solid tumors SAR445611 CX3CR1 Nanobody® VHH Inflammatory indica
Slide 31: Pipeline: regulatory designations since 2020
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Pipeline: regulatory designations since 2020 Orphan drug designation Fast-track designation (US) Breakthrough therapy designation Priority review Dupixent – BP, EoE (US) itepekimab
Slide 32: ESG appendices
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations ESG appendices
Slide 33: ESG: Q2 progress - affordable access
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations ESG: Q2 progress Affordable access Ambition Progress Q2 2024 Q1 2024 Sanofi Reach 1.5 million NCD patients 127,746 patients treated 57,889 patients treated global health by 2026 (c
Slide 34: ESG: Q2 progress - R&D for unmet needs
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations ESG: Q2 progress R&D for unmet needs Ambition Progress FY 2023 FY 2022 Sleeping Develop and supply innovative 2.4 million patients tested 1.5 million patients tested sickness treat
Slide 35: ESG: Q2 progress - planet care
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations ESG: Q2 progress Planet care Ambition Progress Q2 2024 Q1 2024 Climate change - 55% reduction in scope 1&2 43% GHG reduction vs. 2019 42% GHG reduction vs. 2019 carbon footprint gr
Slide 36: ESG: Q2 progress - in and beyond the workplace
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations ESG: Q2 progress In and beyond the workplace Ambition Progress Q2 2024 Q1 2024 Global gender Ambition of 50% of women 45% 45% balance in senior leadership roles by 2025 Ambition of
Slide 37: ESG: ratings
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations ESG: ratings Q2 2024 Climate 18.8 A 77/100 87/100 change: A- B 4.5/5 3.47/5 65/100 Low risk Water: A- Q1 2024 A 21.2 79/100 New A/A- B 4.3/5 3.47/5 65/100 Score stable 17th among 4
Slide 38: Collaborations
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Collaborations Ref Name Developed in collaboration with… A Dupixent itepekimab Regeneron Kevzara B frexalimab ImmuNext C ExPEC9V Vaccine Janssen Pharmaceuticals, Inc., a Johnson &
Slide 39: Abbreviations
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations Abbreviations ACQ-5 Asthma control questionnaire GAA Acid alpha-glucosidase NCD Non-communicable diseases AAT Alpha-1-antitrypsine GCS Glucosylceramide synthase NDMM Newly diagnose
Slide 40: Business Finance Pipeline
Business Finance Pipeline Appendices